Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Blouin Drug: Imlunestrant/camizestrant (SERDs) Company: Lilly and AstraZeneca Indication: ER+ breast cancer Stage: Phase III (pre-NDA) Background: Imlunestrant and camizestrant are two oral selective estrogen receptor degraders (SERDs) aiming to overcome endocrine resistance in ER+, HER2 advanced breast cancer and broaden combination therapy options
These veggie capsules offer delayed-release technology, ensuring that the antioxidant is released slowly for maximum absorption
Selenoprotein P-Expression, functions, and roles in mammals
De Luca P, Cassandro C, Ralli M, et al
US$ 25.57
US$ 25.71
US$ 29.39
